Evogene Ltd Dossier
|
SectorHealth Care IndustryLife Sciences Tools & Services Beta (adjusted)0.80 Intrinsic Value No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference. Market Price $0.44Price as of 1 Oct 2026 Data confidence Sign in to view data confidence Market Cap $6.9M Enterprise Value −$6.1M Shares Outstanding 15.8M diluted Next Earnings Date19 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Evogene Ltd. has successfully pivoted its business model to focus on its proprietary ChemPass AI™ discovery engine, designing and optimizing small molecules for the pharmaceutical and agricultural industries. While near-term financial results reflect a sharp revenue decline due to the wind-down of Casterra's seed operations and the termination of the Bayer herbicide collaboration, the company's strategic shift significantly reduces capital intensity. Backed by a solid cash runway extending into the second half of 2027, a second Google Cloud collaboration integrating AI agents, and an expanding pipeline of pharmaceutical partnerships, Evogene represents a high-upside play on generative AI in computational chemistry. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$2.15 Mean target$2.15 High · most bullish analyst$2.15 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $1.2520% The company struggles to sign new partnerships following the termination of the Bayer collaboration. Cash burn remains high, and the company is forced to raise highly dilutive capital under its ATM program at depressed share prices. Designed molecules face delays in entering preclinical trials, postponing commercial validation of the ChemPass AI engine. Base CaseCentral scenario $2.1550% Matches the consensus meanEvogene steadily executes its computational chemistry strategy, maintaining its current 4 pharmaceutical collaborations and signing several more by early 2027. The company manages its cash burn to ensure liquidity lasts into 2H 2027, supported by the February 2026 warrant inducement proceeds of $3.4 million and the newly established ATM program. Progress in the AgPlenus herbicide program with Corteva continues to validate the platform. Bull CaseUpside scenario $2.5030% Evogene rapidly scales its ChemPass AI platform, securing 10 or more high-value pharmaceutical and agricultural partnerships by early 2027. Designed molecules successfully enter preclinical testing in 1H 2027, triggering substantial milestone payments. Cash runway is further extended by dividend distributions from subsidiaries Lavie Bio and Biomica, alongside non-dilutive R&D grants. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |